Ropinirole therapy for Parkinson's disease

Expert Review of Neurotherapeutics

Volumn 4, Issue 4, 2004, Pages 581-588

  Pahwa, Rajesh ^b   Lyons, Kelly E ^b   Hauser, Robert A ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

Dyskinesia; Motor fluctuations; Parkinson's disease; Restless legs syndrome; Ropinirole; Ropinirole controlled release

Indexed keywords

AMANTADINE; APOMORPHINE; BENZATROPINE MESILATE; BROMOCRIPTINE; BROMOCRIPTINE MESILATE; CABERGOLINE; DIHYDROXYPHENYLALANINE F 18; DOPAMINE 2 RECEPTOR STIMULATING AGENT; ENTACAPONE; ERGOT ALKALOID; FLUORINE 18; LEVODOPA; PERGOLIDE MESILATE; PRAMIPEXOLE; ROPINIROLE; ROTIGOTINE; SELEGILINE; SUMANIROLE; SYMMETRYL; TOLCAPONE; TRIHEXYPHENIDYL; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADJUVANT THERAPY; ANXIETY DISORDER; ARTHRALGIA; ASTHENIA; CELL LOSS; CLINICAL TRIAL; CONFUSION; CONSTIPATION; CONTROLLED DRUG RELEASE; DEPRESSION; DISEASE COURSE; DOPAMINERGIC NERVE CELL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG LIVER LEVEL; DRUG METABOLISM; DRUG TOLERABILITY; DYSKINESIA; DYSPEPSIA; EDEMA; FALLING; FATIGUE; HALLUCINATION; HEADACHE; HUMAN; INSOMNIA; LEG EDEMA; LUNG FIBROSIS; MONOTHERAPY; MOTOR PERFORMANCE; NAUSEA; ON OFF PHENOMENON; ORTHOSTATIC HYPOTENSION; PAIN; PARESTHESIA; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; RESTLESS LEGS SYNDROME; RETROPERITONEAL FIBROSIS; REVIEW; SIDE EFFECT; SOMNOLENCE; SWEATING; SYNCOPE; TREATMENT INDICATION; TREMOR; VERTIGO; VISUAL DISORDER; VOMITING; XEROSTOMIA;

ANTIPARKINSON AGENTS; DOPAMINE AGONISTS; DRUG THERAPY, COMBINATION; HUMANS; INDOLES; LEVODOPA; PARKINSON DISEASE;

EID: 3042697158     PISSN: 14737175     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737175.4.4.581     Document Type: Review

References (41)

1. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N. Engl. J. Med. 342(20), 1484-1491 (2000). The first long-term study examining the onset of dyskinesia in patients randomly assigned to either levodopa or ropinirole.
2. Pramipexole versus levodopa as initial treatment for Parkinson's disease: a randomized controlled trial. Parkinson Study Group. JAMA 284(15), 1931-1938 (2000).
3. Pahwa R, Wilkinson SB, Overman J, Lyons KE. Bilateral subthalamic stimulation in patients with Parkinson's disease: long-term follow-up. J. Neurosurg. 99(1), 71-77 (2003).
4. Coldwell MC, Boyfield I, Brown T, Hagan JJ, Middlemiss DN. Comparison of the functional potencies of ropinirole and other dopamine receptor agonists at human D2(long), D3 and D4.4 receptors expressed in Chinese hamster ovary cells. Br. J. Pharmacol. 127(7), 1696-1702 (1999).
5. Eden RJ, Costall B, Domeney AM et al. Preclinical pharmacology of ropinirole (SK&F 101468-A) a novel dopamine D2 agonist. Pharmacol. Biochem. Behav. 38(1), 147-154 (1991).
6. Jenner P. The rationale for the use of dopamine agonists in Parkinson's disease. Neurology 45(3 Suppl. 3), S6-S12 (1995).
7. Brooks DJ, Torjanski N, Burn DJ. Ropinirole in the symptomatic treatment of Parkinson's disease. J. Neural. Transm. 45, 231-238 (1995).
8. Kaye CM, Nicholls B. Clinical pharmacokinetics of ropinirole. Clin. Pharmacokinet. 39(4), 243-254 (2000).
9. Ramji JV, Keogh JP, Blake TJ et al. Disposition of ropinirole in animals and man. Xenobiotica 29(3), 311-325 (1999).
10. Kuzel MD. Ropinirole: a dopamine agonist for the treatment of Parkinson's disease. Am. J. Health Syst. Pharm. 56(3), 217-224 (1999).
11. Swagzdis JE, Wittendorf RW, DeMarinis RM, Mico BA. Pharmacokinetics of dopamine-2 agonists in rats and dogs. J. Pharm. Sci. 75(10), 925-928 (1986).
12. Bloomer JC, Clarke SE, Chenery RJ. In vitro identification of the P450 enzymes responsible for the metabolism of ropinirole. Drug Metab. Dispos. 25(7), 840-844 (1997).
13. Brefel C, Thalamas C, Rayet S et al. Effect of food on the pharmacokinetics of ropinirole in parkinsonian patients. Br. J. Clin. Pharmacol. 45(4), 412-415 (1998).
14. Beerahee A, Nichols AI, Aluri J et al. Population pharmacokinetics of ropinirole in patients with Parkinson's disease. Br. J. Clin. Pharmacol. 43, 556-557 (1997).
15. Wynalda MA, Wienkers LC. Assessment of potential interactions between dopamine receptor agonists and various human cytochrome P450 enzymes using a simple in vitro inhibition screen. Drug Metab. Dispos. 25(10), 1211-1214 (1997).
16. Fukuzaki K, Kamenosono T, Kitazumi K, Nagata R. Effects of ropinirole on motor behavior in MPTP-treated common marmosets. Pharmacol. Biochem. Behav. 67(1), 121-129 (2000).
17. Pearce RK, Banerji T, Jenner P, Marsden CD. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset. Mov. Disord. 13(2), 234-241 (1998).
18. Adler CH, Sethi KD, Hauser RA et al. Ropinirole for the treatment of early Parkinson's disease. The Ropinirole Study Group. Neurology 49(2), 393-399 (1997).
19. Brooks DJ, Abbott RJ, Lees AJ et al. A placebo-controlled evaluation of ropinirole, a novel D2 agonist, as sole dopaminergic therapy in Parkinson's disease. Clin. Neuropharmacol. 21(2), 101-107 (1998).
20. Korczyn AD, Brunt ER, Larsen JP, Nagy Z, Poewe WH, Ruggieri S. A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson's disease. The 053 Study Group. Neurology 53(2), 364-370 (1999). One of the few randomized studies comparing the safety and efficacy of two dopamine agonists.
21. Rascol O, Lees AJ, Senard JM, Pirtosek Z, Montastruc JI, Fuell D. Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson's disease. Clin. Neuropharmacol. 19(3), 234-245 (1996).
22. Lieberman A, Olanow CW, Sethi K et al. A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease. Ropinirole Study Group. Neurology 51(4), 1057-1062 (1998).
23. Whone AL, Watts RL, Stoessl AJ et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study. Ann. Neurol. 54(1), 93-101 (2003). Examines the progression of disease in patients randomly assigned to ropinirole or levodopa using positron emission tomography imaging as a marker.
24. Iida M, Miyazaki I, Tanaka K, Kabuto H, Iwata-Ichikawa E, Ogawa N. Dopamine D2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist. Brain Res. 838(1-2), 51-59 (1999).
25. Rakshi JS, Pavese N, Uema T et al. A comparison of the progression of early Parkinson's disease in patients started on ropinirole or L-dopa: an 18F-dopa PET study. J. Neural. Trans. 109(12), 1433-1443 (2002).
26. Physicians' Desk Reference (2004).
27. Frucht S, Rogers JD, Greene PE, Gordon MF, Fahn S. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology 52(9), 1908-1910 (1999).
28. Ferreira JJ, Galitzky M, Montastruc JL, Rascol O. Sleep attacks and Parkinson's disease treatment. Lancet 355(9212), 1333-1334 (2000).
29. Ferreira JJ, Thalamas C, Montastruc JL, Castro-Caldas A, Rascol O. Levodopa monotherapy can induce 'sleep attacks' in Parkimon's disease patients. J. Neurol. 248(5), 426-427 (2001).
30. Hobson DE, Lang AE, Martin WR, Razmy A, Rivest J, Fleming J. Excessive daytime sleepiness and sudden-onset sleep in Parkinson's disease: a survey by the Canadian Movement Disorders Group. JAMA 287(4), 455-463 (2002).
31. Todman DH, Oliver WA, Edwards RL. Pleuropulmonary fibrosis due to bromocriptine treatment for Parkinson's disease. Clin. Exp. Neurol. 27, 79-82 (1990).
32. Lanier WL. Additional insights into pergolide-associated valvular heart disease. Mayo Clin. Proc. 78(6), 684-686 (2003).
33. Lund BC, Neiman RF, Perry PJ. Treatment of Parkinson's disease with ropinirole after pergolide-induced retroperitoneal fibrosis. Pharmacotherapy 19(12), 1437-1438 (1999).
34. Lang AE, Lees A. Management of Parkinson's Disease: an evidence-based review. Mov. Disord. 17(S4), S1-S166 (2002). Provides a detailed overview of the various treatments for Parkinson's disease using an evidence-based approach.
35. Miyasaki JM, Martin W, Suchowersky O, Weiner WJ, Lang AE. Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 58(1), 11-17 (2002). Represents the official practice parameters of the American Academy of Neurology for the initiation of treatment for Parkinson's disease using an evidence-based approach.
36. Ondo W. Ropinirole for restless legs syndrome. Mov. Disord. 14(1), 138-140 (1999).
37. Saletu M, Anderer P, Saletu B et al. Sleep laboratory studies in restless leg syndrome patients as compared with normals and acute effects of ropinirole. 2. Findings on periodic leg movements, arousals and respiratory variables. Neuropsychobiology 41(4), 190-199 (2000).
38. Saletu B, Gruber G, Saletu M et al. Sleep laboratory studies in restless legs syndrome patients as compared with normals and acute effects of ropinirole. 1. Findings on objective and subjective sleep and awakening quality. Neuropsychobiology 41(4), 181-189 (2000).
39. Trenkwalder C, Garcia-Borreguero D, Montagna P et al. Ropinirole in the treatment of restless legs syndrome: results from the TREAT RLS 1 study, a 12 week, randomised, placebo-controlled study in 10 European countries. J. Neurol. Neurosurg. Psychiatry 75(1), 92-97 (2004). A large multicenter, randomized trial examining the use of ropinirole for restless legs syndrome.
40. Adler CH, Hauser RA, Sethi K et al. Ropinirole for restless legs syndrome: a placebo-controlled crossover trial. Neurology 62, 1405-1407 (2004).
41. Shulman LM, Minagar A, Rabinstein A, Weiner WJ. The use of dopamine agonists in very elderly patients with Parkinson's disease. Mov. Disord. 15, 664-668 (2000).